Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Verasone™ is an aqueous suspension of the combination of two marketed drugs to be dosed by
sinonasal irrigation in the treatment of Chronic Rhinosinusitis (CRS). This Phase 1
first-in-human study will assess the safety, tolerability, and pharmacokinetics (PK) of
single and multiple ascending doses of Verasone versus placebo in healthy normal participants
and will evaluate the PK profiles of the Verasone active components administered individually
vs in combination.